Hester Biosciences Limited HESTERBIO NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.hester.in

Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella abortus, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming aids, and anti-infective formulations; and healthcare products, such as immune boosters, gut health enhancers, vitamins, minerals and specialty feed supplements, and various formulations for critical needs comprising disease prevention, growth, and nutritional balance. Additionally, the company provides sero-profiling kits, diagnostic labs for poultry flocks, and mastitis control programs for cattle; and manufactures and trades in goods. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Mehsana, India.

Market & Price

Market Cap

₹1,709.20 Cr

Current Price

₹2,009.20

High / Low (52W)

₹2,186.22 / ₹1,259.10

Beta

0.43

Valuation

Stock P/E

29.76

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹423.46

Price to Book

4.74

P/S

5.14

EV/EBITDA

21.98

Dividend Yield

0.35%

Profitability & Returns

ROCE

16.51%

ROE

16.56%

ROA

6.36%

Profit Margin

16.73%

Op Margin

28.39%

EPS (Latest Qtr)

₹19.45

EPS (TTM)

₹67.51

Balance Sheet & Liquidity

Debt/Equity

0.53

Quick Ratio

0.67

Current Ratio

1.37

Debt

₹194.79 Cr

Total Assets

₹677.94 Cr

Current Assets

₹208.56 Cr

Working Capital

₹56.08 Cr

Ownership

Promoter Holding

68.79%

Chg in Prom Hold

FII / Inst Holding

0.27%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹1,905.01 Cr

Total Revenue (TTM)

₹332.60 Cr

EBITDA

₹86.66 Cr

Free Cash Flow

₹36.05 Cr

Operating Cash Flow

₹64.14 Cr

Shares Outstanding

₹85.07 L

Gross Margin

75.36%

Payout Ratio

10.36%

Growth (CAGR)

Revenue 5Y

7.72%

Profit 5Y

27.85%

Revenue (YoY)

38.20%

Earnings (YoY)

968.70%

PROS

Profit CAGR of 27.8% over 5 years.
Generates positive free cash flow.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	HESTERBIO Hester Biosciences Limited NSEPHARMA	2,009.20	29.76	₹1,709.20 Cr	0.35%	16.51%	16.56%	7.72%	27.85%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	81.92 Cr	84.11 Cr	70.97 Cr	77.42 Cr	100.11 Cr
Cost of Revenue	-	-	20.74 Cr	22.46 Cr	19.32 Cr	20.73 Cr	19.45 Cr
Gross Profit	-	-	61.18 Cr	61.64 Cr	51.65 Cr	56.69 Cr	80.66 Cr
Operating Expenses	-	-	46.18 Cr	43.01 Cr	44.29 Cr	43.33 Cr	52.24 Cr
Operating Income	-	-	15.01 Cr	18.63 Cr	7.36 Cr	13.36 Cr	28.42 Cr
EBITDA	-	-	13.54 Cr	26.18 Cr	23.60 Cr	19.78 Cr	36.10 Cr
Interest Expense	5.89 Cr	-	5.62 Cr	1.81 Cr	2.21 Cr	1.82 Cr	5.09 Cr
Pretax Income	-	-	3.75 Cr	20.19 Cr	17.04 Cr	13.52 Cr	25.09 Cr
Tax Provision	-	-	2.20 Cr	2.89 Cr	2.71 Cr	4.21 Cr	8.54 Cr
Net Income	-	-	1.29 Cr	16.44 Cr	14.45 Cr	8.77 Cr	15.98 Cr
Diluted EPS	9.86	-	1.82	20.33	16.85	10.94	19.45

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	266.09 Cr	304.55 Cr	311.10 Cr	332.60 Cr
Cost of Revenue	-	85.82 Cr	110.18 Cr	88.32 Cr	81.96 Cr
Gross Profit	-	180.27 Cr	194.36 Cr	222.78 Cr	250.64 Cr
Operating Expenses	-	138.71 Cr	152.08 Cr	178.53 Cr	182.86 Cr
Operating Income	-	41.56 Cr	42.28 Cr	44.25 Cr	67.78 Cr
EBITDA	-	66.00 Cr	58.25 Cr	69.08 Cr	105.65 Cr
Interest Expense	-	5.15 Cr	9.12 Cr	12.70 Cr	10.93 Cr
Pretax Income	-	40.15 Cr	31.95 Cr	39.57 Cr	75.84 Cr
Tax Provision	-	12.12 Cr	10.79 Cr	10.74 Cr	18.35 Cr
Net Income	-	26.63 Cr	18.89 Cr	27.49 Cr	55.64 Cr
Diluted EPS	46.22	31.30	22.20	33.89	-

Compounded Sales Growth

5 Years:	7.72%
1 Year:	38.20%

Compounded Profit Growth

5 Years:	27.85%
1 Year:	968.70%

Stock Price Performance

1 Year:	+11.16%
6 Months:	+20.18%
3 Months:	+26.76%
1 Month:	+21.36%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	669.97 Cr	662.35 Cr	653.38 Cr	677.94 Cr
Current Assets	-	227.59 Cr	214.62 Cr	195.17 Cr	208.56 Cr
Cash & Equivalents	-	12.67 Cr	12.31 Cr	5.59 Cr	2.77 Cr
Inventory	-	84.81 Cr	75.58 Cr	70.38 Cr	72.53 Cr
Receivables	-	79.63 Cr	78.64 Cr	73.18 Cr	95.36 Cr
Total Liabilities	-	381.42 Cr	359.47 Cr	326.73 Cr	310.15 Cr
Current Liabilities	-	148.70 Cr	105.47 Cr	125.18 Cr	152.48 Cr
Long Term Debt	-	184.81 Cr	182.09 Cr	133.37 Cr	89.96 Cr
Total Debt	-	274.15 Cr	244.38 Cr	213.25 Cr	194.79 Cr
Total Equity	-	279.73 Cr	291.79 Cr	314.25 Cr	360.24 Cr
Shares Outstanding	-	85.07 L	85.07 L	85.07 L	85.07 L

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	23.60 Cr	48.18 Cr	64.51 Cr	64.14 Cr
Investing Cash Flow	-	-77.00 Cr	-22.61 Cr	-19.00 Cr	-2.87 Cr
Financing Cash Flow	-	41.76 Cr	-26.09 Cr	-51.72 Cr	-48.79 Cr
Capital Expenditure	-	-77.76 Cr	-24.40 Cr	-20.59 Cr	-17.83 Cr
Free Cash Flow	-	-54.17 Cr	23.79 Cr	43.92 Cr	46.31 Cr
Net Change in Cash	-	-11.64 Cr	-51.60 L	-6.21 Cr	12.48 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	67.7%	63.8%	71.6%	75.4%
Operating Margin %	-	15.6%	13.9%	14.2%	20.4%
Net Margin %	-	10.0%	6.2%	8.8%	16.7%
ROE %	-	9.5%	6.5%	8.7%	15.4%
ROCE %	-	8.0%	7.6%	8.4%	12.9%

Shareholding Pattern

Insiders

68.79%

Institutions

0.27%

Public Float

0.86%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HESTERBIO

No recent headlines available.

HESTERBIO · Healthcare